Verastem draws $55m in initial public offering
The Boston Globe Cambridge News
Jan 28Verastem Inc., a Cambridge company that is seeking to create drugs that target cancer stem cells, launched on the Nasdaq Stock Market yesterday, opening at $11 a share, up from its initial public offering price of $10. It sold 5.5 million shares, raisi... »